Yin, F., Yang, J., Luo, H., Yu, T., Lu, W., Zhao, M., . . . Hu, Y. Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids. Nature Publishing Group.
Chicago Style (17th ed.) CitationYin, Feng, et al. Targeting Oncogenic Activation of FLT3/SREBP/FASN Promotes the Therapeutic Effect of Quizartinib Involving Disruption of Mitochondrial Phospholipids. Nature Publishing Group.
MLA (9th ed.) CitationYin, Feng, et al. Targeting Oncogenic Activation of FLT3/SREBP/FASN Promotes the Therapeutic Effect of Quizartinib Involving Disruption of Mitochondrial Phospholipids. Nature Publishing Group.
Warning: These citations may not always be 100% accurate.